Drug
BIIB092
BIIB092 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 20.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
20.0%
Based on 1 completed trials
Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
4(80%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
20.0%
1 of 5 finished
Non-Completion Rate
80.0%
4 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(1)
Terminated(4)
Detailed Status
Terminated4
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed120%
terminated480%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_2
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
NCT03352557
terminatedphase_2
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
NCT03068468
terminatedphase_1
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
NCT02658916
terminatedphase_1
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
NCT03658135
completedphase_1
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
NCT02460094
Clinical Trials (5)
Showing 5 of 5 trials
NCT03352557Phase 2
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
NCT03068468Phase 2
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
NCT02658916Phase 1
Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
NCT03658135Phase 1
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
NCT02460094Phase 1
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5